Inhibition of WY-14,643 induced hepatic lesion growth in mice by rotenone

Jason S. Isenberg, Kyle L. Kolaja, Siar A. Ayoubi, John B. Watkins, James E. Klaunig

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The effect of rotenone treatment on [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) hepatic lesion growth in male B6C3F1 mice was investigated. Following induction of hepatic focal lesions by diethylnitrosamine (DEN) 35 mg/kg twice a week for 8 weeks, mice were placed into one of the four treatment groups: group I, control NIH-07 diet (control diet), group II, rotenone (600 mg/kg diet), group III NIH-07 diet containing WY-14,643 (1000 mg/kg diet), and group IV, NIH-07 diet containing WY-14,643 (1000 mg/kg diet) and rotenone (600 mg/kg diet). Mice were killed after 30 and 60 days of dietary treatment. The effect of treatment with WY-14,643 and rotenone on hepatic lesion growth was examined by estimating the number of focal lesions per liver and the relative volume of focal lesions. WY-14,643 (group III) increased both the number and the volume of focal lesions. In particular, an increase in number and volume of basophilic lesions was seen. Co-treatment with WY-14,643 and rotenone (group IV) decreased both the number and the volume of the total number of focal lesions and basophilic foci compared with WY-14,643 treatment alone (group II). Alterations in the growth of hepatic focal lesions was further investigated by examining DNA synthesis and apoptosis within individual lesions. WY-14,643 (group III) treatment increased the DNA synthetic labeling index in all foci. Co-treatment of rotenone and WY-14,643 (group IV) decreased focal DNA synthesis and mitosis and increased the incidence of apoptotic hepatocytes. These data suggest that rotenone's ability to inhibit WY-14,643-induced hepatic focal lesion growth was mediated through a decrease in hepatic focal proliferation and an increase in focal apoptosis.

Original languageEnglish
Pages (from-to)1511-1519
Number of pages9
JournalCarcinogenesis
Volume18
Issue number8
DOIs
StatePublished - Aug 1997

Fingerprint

Rotenone
Liver
Growth
Diet
DNA
pirinixic acid
Apoptosis
Diethylnitrosamine
Mitosis
Hepatocytes

ASJC Scopus subject areas

  • Cancer Research

Cite this

Isenberg, J. S., Kolaja, K. L., Ayoubi, S. A., Watkins, J. B., & Klaunig, J. E. (1997). Inhibition of WY-14,643 induced hepatic lesion growth in mice by rotenone. Carcinogenesis, 18(8), 1511-1519. https://doi.org/10.1093/carcin/18.8.1511

Inhibition of WY-14,643 induced hepatic lesion growth in mice by rotenone. / Isenberg, Jason S.; Kolaja, Kyle L.; Ayoubi, Siar A.; Watkins, John B.; Klaunig, James E.

In: Carcinogenesis, Vol. 18, No. 8, 08.1997, p. 1511-1519.

Research output: Contribution to journalArticle

Isenberg, JS, Kolaja, KL, Ayoubi, SA, Watkins, JB & Klaunig, JE 1997, 'Inhibition of WY-14,643 induced hepatic lesion growth in mice by rotenone', Carcinogenesis, vol. 18, no. 8, pp. 1511-1519. https://doi.org/10.1093/carcin/18.8.1511
Isenberg JS, Kolaja KL, Ayoubi SA, Watkins JB, Klaunig JE. Inhibition of WY-14,643 induced hepatic lesion growth in mice by rotenone. Carcinogenesis. 1997 Aug;18(8):1511-1519. https://doi.org/10.1093/carcin/18.8.1511
Isenberg, Jason S. ; Kolaja, Kyle L. ; Ayoubi, Siar A. ; Watkins, John B. ; Klaunig, James E. / Inhibition of WY-14,643 induced hepatic lesion growth in mice by rotenone. In: Carcinogenesis. 1997 ; Vol. 18, No. 8. pp. 1511-1519.
@article{735bdeabf97f45ae8389d7414365c9c4,
title = "Inhibition of WY-14,643 induced hepatic lesion growth in mice by rotenone",
abstract = "The effect of rotenone treatment on [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) hepatic lesion growth in male B6C3F1 mice was investigated. Following induction of hepatic focal lesions by diethylnitrosamine (DEN) 35 mg/kg twice a week for 8 weeks, mice were placed into one of the four treatment groups: group I, control NIH-07 diet (control diet), group II, rotenone (600 mg/kg diet), group III NIH-07 diet containing WY-14,643 (1000 mg/kg diet), and group IV, NIH-07 diet containing WY-14,643 (1000 mg/kg diet) and rotenone (600 mg/kg diet). Mice were killed after 30 and 60 days of dietary treatment. The effect of treatment with WY-14,643 and rotenone on hepatic lesion growth was examined by estimating the number of focal lesions per liver and the relative volume of focal lesions. WY-14,643 (group III) increased both the number and the volume of focal lesions. In particular, an increase in number and volume of basophilic lesions was seen. Co-treatment with WY-14,643 and rotenone (group IV) decreased both the number and the volume of the total number of focal lesions and basophilic foci compared with WY-14,643 treatment alone (group II). Alterations in the growth of hepatic focal lesions was further investigated by examining DNA synthesis and apoptosis within individual lesions. WY-14,643 (group III) treatment increased the DNA synthetic labeling index in all foci. Co-treatment of rotenone and WY-14,643 (group IV) decreased focal DNA synthesis and mitosis and increased the incidence of apoptotic hepatocytes. These data suggest that rotenone's ability to inhibit WY-14,643-induced hepatic focal lesion growth was mediated through a decrease in hepatic focal proliferation and an increase in focal apoptosis.",
author = "Isenberg, {Jason S.} and Kolaja, {Kyle L.} and Ayoubi, {Siar A.} and Watkins, {John B.} and Klaunig, {James E.}",
year = "1997",
month = "8",
doi = "10.1093/carcin/18.8.1511",
language = "English",
volume = "18",
pages = "1511--1519",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Inhibition of WY-14,643 induced hepatic lesion growth in mice by rotenone

AU - Isenberg, Jason S.

AU - Kolaja, Kyle L.

AU - Ayoubi, Siar A.

AU - Watkins, John B.

AU - Klaunig, James E.

PY - 1997/8

Y1 - 1997/8

N2 - The effect of rotenone treatment on [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) hepatic lesion growth in male B6C3F1 mice was investigated. Following induction of hepatic focal lesions by diethylnitrosamine (DEN) 35 mg/kg twice a week for 8 weeks, mice were placed into one of the four treatment groups: group I, control NIH-07 diet (control diet), group II, rotenone (600 mg/kg diet), group III NIH-07 diet containing WY-14,643 (1000 mg/kg diet), and group IV, NIH-07 diet containing WY-14,643 (1000 mg/kg diet) and rotenone (600 mg/kg diet). Mice were killed after 30 and 60 days of dietary treatment. The effect of treatment with WY-14,643 and rotenone on hepatic lesion growth was examined by estimating the number of focal lesions per liver and the relative volume of focal lesions. WY-14,643 (group III) increased both the number and the volume of focal lesions. In particular, an increase in number and volume of basophilic lesions was seen. Co-treatment with WY-14,643 and rotenone (group IV) decreased both the number and the volume of the total number of focal lesions and basophilic foci compared with WY-14,643 treatment alone (group II). Alterations in the growth of hepatic focal lesions was further investigated by examining DNA synthesis and apoptosis within individual lesions. WY-14,643 (group III) treatment increased the DNA synthetic labeling index in all foci. Co-treatment of rotenone and WY-14,643 (group IV) decreased focal DNA synthesis and mitosis and increased the incidence of apoptotic hepatocytes. These data suggest that rotenone's ability to inhibit WY-14,643-induced hepatic focal lesion growth was mediated through a decrease in hepatic focal proliferation and an increase in focal apoptosis.

AB - The effect of rotenone treatment on [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) hepatic lesion growth in male B6C3F1 mice was investigated. Following induction of hepatic focal lesions by diethylnitrosamine (DEN) 35 mg/kg twice a week for 8 weeks, mice were placed into one of the four treatment groups: group I, control NIH-07 diet (control diet), group II, rotenone (600 mg/kg diet), group III NIH-07 diet containing WY-14,643 (1000 mg/kg diet), and group IV, NIH-07 diet containing WY-14,643 (1000 mg/kg diet) and rotenone (600 mg/kg diet). Mice were killed after 30 and 60 days of dietary treatment. The effect of treatment with WY-14,643 and rotenone on hepatic lesion growth was examined by estimating the number of focal lesions per liver and the relative volume of focal lesions. WY-14,643 (group III) increased both the number and the volume of focal lesions. In particular, an increase in number and volume of basophilic lesions was seen. Co-treatment with WY-14,643 and rotenone (group IV) decreased both the number and the volume of the total number of focal lesions and basophilic foci compared with WY-14,643 treatment alone (group II). Alterations in the growth of hepatic focal lesions was further investigated by examining DNA synthesis and apoptosis within individual lesions. WY-14,643 (group III) treatment increased the DNA synthetic labeling index in all foci. Co-treatment of rotenone and WY-14,643 (group IV) decreased focal DNA synthesis and mitosis and increased the incidence of apoptotic hepatocytes. These data suggest that rotenone's ability to inhibit WY-14,643-induced hepatic focal lesion growth was mediated through a decrease in hepatic focal proliferation and an increase in focal apoptosis.

UR - http://www.scopus.com/inward/record.url?scp=0031431669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031431669&partnerID=8YFLogxK

U2 - 10.1093/carcin/18.8.1511

DO - 10.1093/carcin/18.8.1511

M3 - Article

VL - 18

SP - 1511

EP - 1519

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 8

ER -